Lpath Demonstrates Preclinical Efficacy Of Lpathomab(TM) And Initiates Humanization Process

Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported positive results in several murine models of human cancer and AMD with Lpathomab(TM), the company’s mouse monoclonal antibody against LPA (lysophosphatidic acid). These results confirm the expected potent anti angiogenic and anti metastatic actions of Lpathomab. Lpathomab was created using Lpath’s proprietary ImmuneY2(TM) platform technology. [click link for full article]

More: continued here

Filed under: Biology on September 6th, 2007